Loading clinical trials...
Loading clinical trials...
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amgen
NCT06314919 · Primary Hypercholesterolemia, Mixed Dyslipidemia
NCT06932705 · Mixed Dyslipidemia
NCT06568471 · Hypercholesterolemia, Dyslipidemias, and more
NCT05400317 · Mixed Dyslipidemia
NCT05621070 · Primary Hypercholesterolaemia and Mixed Dyslipidemia
Research Site
Phoenix, Arizona
Research Site
Encino, California
Research Site
Thousand Oaks, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions